Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) Director Nicholas Galakatos sold 1,369 shares of Portola Pharmaceuticals stock on the open market in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $23.36, for a total value of $31,979.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Portola Pharmaceuticals (NASDAQ:PTLA) traded up 1.27% on Thursday, hitting $24.66. The stock had a trading volume of 57,009 shares. Portola Pharmaceuticals has a 52 week low of $18.25 and a 52 week high of $30.95. The stock’s 50-day moving average is $22.64 and its 200-day moving average is $24.91. The company’s market cap is $1.014 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Monday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter in the previous year, the company posted ($12.94) earnings per share. The company’s revenue for the quarter was down 23.8% on a year-over-year basis. Analysts expect that Portola Pharmaceuticals will post $-3.44 EPS for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.